Final Stage 1 Results of the Phase III CLL11 Trial of Chlorambucil with Obinutuzumab or Rituximab in Previously Untreated CLL


Final Stage 1 Results of the Phase III CLL11 Trial of Chlorambucil with Obinutuzumab or Rituximab in Previously Untreated CLL
Slides from a presentation at ASCO 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (9/10/13)

Goede V et al. Obinutuzumab (GA101) + chlorambucil (Clb) or rituximab (R) + Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): Final Stage I results of the CLL11 (BO21004) Phase 3 trial. Proc ASCO 2013;Abstract 7004.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.